The Methodist Hospital

The Methodist Hospital Research Institute

Rita Elena Serda

Ismail Mustafa Meraz

Mauro Ferrari

Tong Sun

Jianhua Gu

Haifa Shen

Xiaojun Xia

Disclosed are positively-charged, cytotoxic nanoparticle compositions comprising immune modulators (such as the toll-like receptor (TLR)-4 ligand, monophosphoryl lipid (MPL)-A), and Interleukin (IL)-12)), which exhibit enhanced uptake by mammalian cancer cells, and cause increased cancer cell death and/or an increased release of cancer antigens following direct injection to populations of cancer or tumor cells. Also disclosed are nanoparticle-vectored, immunomodulatory compositions that stimulate antigen presenting immune cells and T cells, and support the development of anti-cancer immunity in mammalian hosts. The disclosed cationic liposomes represent an important advance in the area of cancer immunotherapeutics.

Cationic liposomes for cancer immunotherapy

Disclosed are mesoporous silicon multi-stage vehicles that comprise liposomal-based second-stage particles, as well as pharmaceutical compositions and formulations including such vectors for use in a variety of diagnostic and therapeutic indications. In particular embodiments, MSV comprising ligand decorated second-stage particles are provided for therapeutic methods including, for example, treatment of mammalian cancers, including those of the human breast.

Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity

Growing community of inventors

Pearland, TX, United States of America

Rita Elena Serda